Recommendations on current approach to gastric cancer

Clinical and Translational Oncology

Volumn 11, Issue 8, 2009, Pages 518-525

  Rivera, Fernando ^a   Carrato, Alfredo ^b   Grávalos, Cristina ^c   Pericay, Carles ^d   Sastre, Javier ^e   Aranda, Enrique ^f  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d Servicio de Cirugía General Y Aparato Digestivo   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Chemotherapy; Complementary treatment; Gastric cancer; Multidisciplinary management; New target oriented drugs; Recommendations

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; CANCER STAGING; CLINICAL TRIAL; HEALTH CARE PLANNING; HUMAN; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; STOMACH TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HEALTH PLANNING GUIDELINES; HUMANS; NEOPLASM STAGING; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 74049161311     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-009-0396-9     Document Type: Article

References (56)

1. Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592
2. Área de Epidemiología Ambiental y Cáncer. Centro Nacional de Epidemiología Instituto de Salud Carlos III. La situación del cáncer en España. Ministerio de Sanidad y Consumo
3. Cunningham D, Jost LM, Purkalne G, Oliveira J, coordinating authors for the ESMO Guidelines Task Force (2005) ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer. Ann Oncol 16[Suppl 1]:22-23
4. Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York
5. Bozzetti F (2002) Rationale and indications for preoperative feeding of malnourished surgical cancer patients. Nutrition 18:953-959
6. Corish CA (1999) Pre-operative nutritional assessment. Proc Nutr Soc 58:821-829
7. Barrera R (2002) Nutritional support in cancer patients. JPEN J Parenter Enteral Nutr 26[5 Suppl]:S63-71
8. Kruizenga HM, Van Tulder MW, Seidell JC et al (2005) Effectiveness and cost-effectiveness of early screening and treatment of malnourished patients. Am J Clin Nutr 82:1082-1089
9. Brennan MF, Karpeh MS Jr (1996) Surgery for gastric cancer: The American view. Semin Oncol 23:352
10. Robertson CS, Chung SC, Woods SD et al (1994) A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 220:176-182
11. Gouzi JL, Huguier M, Fagniez PL et al (1989) Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 209:162-166
12. Bozzetti F, Marubini E, Bonfanti G et al (1999) Subtotal versus total gastrectomy for gastric cancer: Fi ve-year survival rates in a multicenter randomized Italian trial-Italian Gastrointestinal Tumor Study Group. Ann Surg 230:170-178
13. Bonenkamp JJ, Songun I, Hermans J et al (1995) Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 345:745-748
14. Cuschieri A, Fayers P, Fielding J et al (1996) Postoperative morbidity and mortality after R1 and R2 resection for gastric cancer: Results of the MRC surgical trial. Lancet 347:995-999
15. Jansen EPM, Boot H, Verheij M, van de Velde CJ (2005) Optimal locoregional treatment in gastric cancer. J Clin Oncol 23:4509-4517
16. Hermans J, Bonenkamp JJ, Boon MC et al (1993) Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials. J Clin Oncol 11:1441-1447
17. Earle CC, Maroun JA (1999) Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomised trials. Eur J Cancer 35:1059-1064
18. Mari E, Floriani I, Tinazzi A et al (2000) Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi delĺApparato Digerente. Ann Oncol 11:837-843
19. Panzini I, Gianni L, Fattori PP et al (2002) Adjuvant chemotherapy in gastric cancer: A metaanalysis of randomized trials and a comparison with previous meta-analysis. Tumori 88:21-27
20. Janunger KG, Hafstrom L, Glimelius B (2002) Chemotherapy in gastric cancer: A review and updated meta-analysis. Eur J Surg 168:597-608
21. Sakamoto J Paoletti X, on behalf of the Global Adv/Adj Stomach Tumor Research through International Collaboration (GASTRIC) (2008) Metaanalyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy in gastric cancer. J Clin Oncol 26[18 Suppl]:abstr 4543
22. Sakuramoto S, Sasako M, Yamaquchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fl uoropyrimidine. N Engl J Med 357:1810-1820
23. Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730
24. Macdonald JS, Benedetti J, Smalley S et al (2009) Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 27[18 Suppl]:abstr 4515
25. Macdonald JS, Smalley S, Benedetti J et al (2004) Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: Update of the results of Intergroup Study INT-0116 (SWOG 9008). 2004 Gastrointestinal Cancers Symposium. Abstr 6
26. Cunningham D, Allum WH, Stening SP, Weeden S (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20
27. Boige V, Pignon J, Saint-Aubert B et al (2007) Final results of a randomized trial comparing preoperative 5-fluorouracil/cisplatin to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07 FFCD 9703 trial. J Clin Oncol 25[18 Suppl]:abstr 4510
28. Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909
29. Sastre J, Garcia-Saenz JA, Díaz-Rubio E (2006) Chemotherapy for gastric cancer. World J Gastroenterol 14:204-213
30. Rivera F, Vega-Villegas ME, López-Brea M (2007) Chemotherapy of advanced gastric cancer. Cancer Treat Rev 33:315-324
31. Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and 5FU vs 5FU, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267
32. Vanhoefer U, Rougier P, Wilke H et al (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and 5FU versus infusional 5FU and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18:2648-2657
33. Ajani JA, Fodor MB, Tjulandin SA et al (2005) Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23:5660-5667
34. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 24:4991-4997
35. Roth AD, Fazio N, Stupp R et al (2007) Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: A randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 25:3217-3223
36. Cunningham D, Starling N, Rao S et al (2008) Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46
37. Kang Y, Kang WK, Shin DB et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial. Ann Oncol 20:666-673
38. Chun J, Kim H, Lee J et al (2005) Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 28:188-194
39. Lorenzen S, Duyster J, Lersch C et al (2005) Three-weekly docetaxel (T) plus capecitabine (X) in 1st and 2nd line metastatic esophageal cancer (MEC): Final results of the phase II DACAPO Trial. J Clin Oncol 23[16 Suppl]:abstr 4142
40. Kim J, Sohn S, Kim D et al (2005) Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 68:190-195
41. Thuss-Patience P, Kretzschmar A, Loew A et al (2005) Capecitabine and docetaxel in advanced gastric adenocarcinoma, an ongoing Phase II study. J Clin Oncol 23:abstr 4224
42. Giordano K, Jatoi A, Stella P et al North Central Cancer Treatment Group (2006) Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: A Phase II study from the North Central Cancer Treatment Group. Ann Oncol 17:652-656
43. Dank M, Zaluski J, Barone C et al (2008) Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19:1450-1457
44. Ajani JA, Rodriquez W, Bodoky G et al (2009) Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. J Clin Oncol 27[15 Suppl]:abstr 4511
45. Thuss-Patience PC, Kretzschmar A, Deist T et al (2009) Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 27[Suppl 18]:abstr 4540
46. Tabernero J (2008) Molecular therapies in esophageal and gastric cancer. Are we on target? Gastrointestinal Cancers Symposium, ASCO, Orlando, FL, 17-18
47. Pinto C, Di Fabio F, Siena S et al (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastro-esophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18:510-517
48. Lordick F, Lorenzen S, Hegewisch-Becker S et al (2007) Cetuximab plus weekly oxaliplatin/5FU/LV in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group. J Clin Oncol 25:abstr 4526
49. Tanner M, Hollmen M, Junttila TT et al (2005) Amplification of HER-2 in gastric carcinoma: Association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16:273-278
50. Lordick F, Bang YJ, Kang YK et al (2007) HER2-positive advanced gastric cancer: Similar HER2-positivity levels to breast cancer. Eur J Cancer 5:271
51. Grávalos C, Jimeno A (2008) HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523-1529
52. Gravalos C, Márquez A, García-Carbonero R et al (2007) Correlation between Her2/neu overexpression/amplification and clinicopathological parameters in advanced gastric cancer patients: A prospective study. Gastrointestinal Cancers Symposium abstr 89
53. Van Cutsem E, Kang Y, Chung H et al (2009) Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27[18 Suppl]:abstr LBA4509
54. Rech J, Arnold D, Folprecht G et al (2006) A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER-2 positive gastric cancer. ESMO abstr 1096
55. Enzinger PC, Ryan DP, Regan EM et al (2008) Phase II trial of docetaxel, cisplatin, irinotecan and bevacizumab in metastatic esophagogastric cancer. Gastrointestinal Cancers Symposium abstr 97
56. Shah MA, Ramanathan RK, Ilson D et al (2006) Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI #6447). J Clin Oncol 24:5201-5206